Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
about
FGF23 in Acute and Chronic IllnessOptimal management of bone mineral disorders in chronic kidney disease and end stage renal diseaseRecent advances in CKD and ESRD: A literature update.Phosphate binders in chronic kidney disease: a systematic review of recent data.Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D StudyNovel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus.Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on DialysisThe role of fibroblast growth factor 23 and Klotho in uremic cardiomyopathy.Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching.FGF23 promotes myocardial fibrosis in mice through activation of β-catenin.Dietary Sources of Phosphorus among Adults in the United States: Results from NHANES 2001-2014.Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative reviewCinacalcet and Clinical Outcomes in Dialysis.Calcimimetic and Calcilytic Drugs: Feats, Flops, and Futures.Calcifediol to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.Chronic Kidney Disease-Mineral and Bone Disorder in Asia.Pathophysiology of cardiorenal syndrome in patients with heart failure: Potential therapeutic targets.FGF23 from bench to bedside.Prognostic value of FGF23 among patients with end-stage renal disease: a systematic review and meta-analysis.Heart failure and kidney dysfunction: epidemiology, mechanisms and management.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Sources of Mortality on Dialysis with an Emphasis on Microemboli.Extrarenal effects of FGF23.Dialysate Composition for Hemodialysis: Changes and Changing Risk.A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemoMineral metabolism and cardiovascular disease in CKD.Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder.Association of inflammatory, lipid and mineral markers with cardiac calcification in older adults.Secondary hyperparathyroidism prevalence and prognostic role in elderly males with heart failure.Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.Where is the link between mineral bone markers and cardiovascular disease in CKD?FGF23 in chronic kidney disease: are we lost in translation?Parathyroidectomy or Calcimimetic to Treat Hypercalcemia after Kidney Transplantation?From Phosphaturia to Cardiovascular Protection: Is Fibroblast Growth Factor-23 the Heart of the Matter?Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis.Role of Vitamin D in Cardiovascular Diseases.Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Calcium Homeostasis in Health and in Kidney Disease.
P2860
Q26778554-B1289E64-8449-473F-995C-0224D08DB13EQ28072340-32603072-C050-4D1F-A5E9-A18319FFF899Q30275339-2960FA2F-39D3-4C7D-B961-174510DE50D0Q31039292-139A1238-2E37-4779-8A37-4EC29E228C5EQ36169244-F2255557-79CC-4D70-808E-219FA1421F23Q36225208-06A6C2EC-A2CC-4EFF-BFD6-FF75657174CAQ36520483-77F1F9B2-B4AD-4CB9-BCF6-54BEC8EA0C18Q36687041-8EC7CC88-E169-4DD6-B7A5-C22EC908B85EQ36963471-AC8A7157-3E41-43A8-A135-11528CC531C9Q37615224-57586C90-58F8-4459-9FBD-8532F102142DQ37662106-05A82A88-E7DB-404C-B48B-763E5223479DQ37673108-B700AC81-EC06-40B2-BF85-E3B0F94451D2Q37695914-3ECC97CC-5A0B-4156-B61A-6CB2C939F187Q38565049-6E50DBCA-E5C4-47C8-836A-B81F304D2CBFQ38576402-E046A575-9883-4D8D-BC4F-127D92084FDDQ38605841-0F7E7275-0F2D-4034-8F74-A285CD1EF807Q38627241-61B9208E-09C3-451E-81C7-9E11DABCE5F0Q38635767-F2095D01-36E4-4643-A4F7-A64F5C67D29BQ38667232-B9C74154-4DF0-42A8-84E4-0A7ED48A99F1Q38728860-019189ED-54B7-48F0-82A8-882BDFC84A0CQ38807804-115737F7-B3A5-4648-ADCB-BC097A200402Q38826590-23F94FD3-2052-4888-8DBF-1A0F93F83CC8Q38828618-7C1D89DB-FF1C-4436-B77A-FC52E00750C9Q38928458-C259C897-63DC-4D27-9195-3C42AE72199EQ38972469-E38CAD11-7573-4DA0-A39B-B8C879DA1FC0Q39032556-2752B502-4BC3-47D7-8F6D-F6B330E5DEF0Q39037214-5504E254-FCCA-4361-8A67-1AB7E5BB9F0FQ39072097-DBF749B3-FBCE-4AA0-9A4E-7397B219C119Q39271483-5AD6751B-B945-4113-9464-3C0D7DBABF25Q39605259-998F42FA-77FE-43EA-A249-FC5764A8737BQ40542661-0048E2F8-8AE4-45F4-9F1D-D8E2A02E3088Q40996542-36DEAA41-67A7-4A62-B024-4B98A95ACF1BQ41880565-C77BEE77-A522-4F3C-B4B4-23B1B610D76FQ41890926-E746CAFA-17A0-47CE-839F-842615EFA99CQ42371167-1C0D6983-6DF6-4422-9298-37503B166C5CQ42419216-B22EF2EF-3D28-4B3B-B4F2-46051DEACAC3Q43475954-0D68D30C-D0CB-408E-AB5A-E109A89F4B41Q46209230-FF4D136B-4EB6-4835-ADB5-56D8D48990B1Q47216784-2535BDF2-4E9E-417A-A536-E8DE522690E2Q48038085-51DBC9AC-76DA-4310-93C8-AC0CC4BBB7B5
P2860
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Cinacalcet, Fibroblast Growth ...... ascular Events (EVOLVE) Trial.
@en
type
label
Cinacalcet, Fibroblast Growth ...... ascular Events (EVOLVE) Trial.
@en
prefLabel
Cinacalcet, Fibroblast Growth ...... ascular Events (EVOLVE) Trial.
@en
P2093
P1433
P1476
Cinacalcet, Fibroblast Growth ...... ascular Events (EVOLVE) Trial.
@en
P2093
Bastian Dehmel
Charles A Herzog
David C Wheeler
Evaluation of Cinacalcet HCl T ...... (EVOLVE) Trial Investigators*
Geoffrey A Block
Gerard M London
Glenn M Chertow
Jürgen Floege
Maria Stolina
Patrick S Parfrey
P356
10.1161/CIRCULATIONAHA.114.013876
P407
P577
2015-06-09T00:00:00Z